Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source

In a randomized trial involving patients who had a first stroke from an embolus of unknown source, rivaroxaban at a daily dose of 15 mg did not result in a lower incidence of recurrent stroke than aspirin at a dose of 100 mg. Bleeding rates were higher with rivaroxaban.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	NEW ENGLAND JOURNAL OF MEDICINE 2018-06, Vol.378 (23), p.2191-2201
Hauptverfasser:	Hart, Robert G, Sharma, Mukul, Mundl, Hardi, Kasner, Scott E, Bangdiwala, Shrikant I, Berkowitz, Scott D, Swaminathan, Balakumar, Lavados, Pablo, Wang, Yongjun, Wang, Yilong, Davalos, Antonio, Shamalov, Nikolay, Mikulik, Robert, Cunha, Luis, Lindgren, Arne, Arauz, Antonio, Lang, Wilfried, Czlonkowska, Anna, Eckstein, Jens, Gagliardi, Rubens J, Amarenco, Pierre, Ameriso, Sebastian F, Tatlisumak, Turgut, Veltkamp, Roland, Hankey, Graeme J, Toni, Danilo, Bereczki, Daniel, Uchiyama, Shinichiro, Ntaios, George, Yoon, Byung-Woo, Brouns, Raf, Endres, Matthias, Muir, Keith W, Bornstein, Natan, Ozturk, Serefnur, O’Donnell, Martin J, De Vries Basson, Matthys M, Pare, Guillaume, Pater, Calin, Kirsch, Bodo, Sheridan, Patrick, Peters, Gary, Weitz, Jeffrey I, Peacock, W. Frank, Shoamanesh, Ashkan, Benavente, Oscar R, Joyner, Campbell, Themeles, Ellison, Connolly, Stuart J
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anticoagulants antithrombotic therapy Aspirin Aspirin - adverse effects Aspirin - therapeutic use Atherosclerosis atrial-fibrillation Bleeding Blood clots Brain Ischemia - prevention & control Cardiac and Cardiovascular Systems Cardiac arrhythmia Clinical Medicine cryptogenic stroke Design Drug dosages efficacy Embolism Embolisms Factor Xa Inhibitors - adverse effects Factor Xa Inhibitors - therapeutic use Female foramen ovale closure General & Internal Medicine Hemorrhage Hemorrhage - chemically induced Hospitals Human health and pathology Humans Internal medicine Intracranial Embolism - drug therapy Ischemia Kaplan-Meier Estimate Kardiologi Klinisk medicin Life Sciences Male Medical and Health Sciences Medical research Medicin och hälsovetenskap Medicine metaanalysis Middle Aged Neurology Neurosciences Patients Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Prevention R&D Research & development Research centers Rivaroxaban - adverse effects Rivaroxaban - therapeutic use safety Secondary Prevention - methods Stenosis Stroke Stroke - etiology Stroke - prevention & control Thrombosis trials warfarin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a randomized trial involving patients who had a first stroke from an embolus of unknown source, rivaroxaban at a daily dose of 15 mg did not result in a lower incidence of recurrent stroke than aspirin at a dose of 100 mg. Bleeding rates were higher with rivaroxaban.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1802686